About Innovative Biotech

Innovative Biotech LTD (IB) was founded in 2006 in Nigeria by Dr. Simon Agwale, a leading African virologist and vaccinologist trained in the US and carrying out research in the US and Nigeria. IB was founded with the mission to provide and enhance better health and life expectancy by eradication of diseases in Africa through the innovative production of biotech products and services.

In 2018, Dr Agwale started firming up plans to build a vaccines manufacturing facility in Nigeria, following the development of his Ebola vaccine. He built a relationship with Merck which would help him with the technical aspects of building a manufacturing facility.

Dr Agwale’s vaccines are based on the VLP vaccines technology which is explained further in this document. When discussions of the COVID-19 infection started in late 2019, Dr Agwale pivoted his strategy to first producing a COVID vaccine, and pushed back his work on the Ebola vaccine. Since Africa was likely to need an urgent supply of COVID vaccines, it made sense to Dr Agwale that he could contribute to the needs of the African continent. Merck introduced Dr Agwale to a US company that owned a COVID vaccine technology based on VLP vaccines, and the technology was licensed (global exclusive licence) to Innovative Biotech.

Innovative Biotech is unique in that:

1. The company owns intellectual property for 2 vaccines for Ebola and HIV with proven efficiency in animal studies.
2. The company has an exclusive global licence for a COVID vaccine which is ready for human clinical trials.
3. The company has a strong working partnership with Merck, which is providing access to all equipment and supply manufacturers needed to set up the manufacturing facility in Africa with low technical and regulatory risks
4. The company has licences from Bharat Biotech for 2 vaccines for Typhoid and Rota virus, which are already approved for human use and which can be manufactured and sold immediately.